INTRODUCTION
Kidney cancer is one of the 10 most common cancers in the developed world. The most common form of kidney cancer is clear cell renal cell carcinoma (ccRCC), which is often linked to mutational inactivation or hypermethylation of the VHL tumor suppressor gene. The VHL gene product, von Hippel-Lindau tumor suppressor protein (pVHL), forms a ubiquitin ligase that targets the a subunits of the heterodimeric hypoxia-inducible factor (HIF) transcription factor for destruction in an oxygen-dependent manner. When oxygen is present, HIFa is prolylhydroxylated by the EglN prolyl hydroxylases [also called prolyl hydroxylase domain (PHDs)] and recognized by pVHL. The EglNs are 2-oxoglutarate-dependent dioxygenases that respond to changes in oxygen over a physiologically relevant concentration range (1, 2) . When oxygen is low, EglN activity decreases and transcriptionally active HIFa accumulates. Deregulation of HIFa, and particularly HIF2a, drives the development of pVHL-defective ccRCC (3) .
VHL inactivation is an early "gatekeeper" event in ccRCC but is not sufficient to cause ccRCC (3) (4) (5) (6) . Additional genetic changes that cooperate with VHL loss to promote tumorigenesis include loss of chromosome 14q and gain of chromosome 5q (7, 8) , as well as intragenic mutations that frequently affect chromatin regulators, such as BAF180, BAF250, BRG1, BAP1, KDM6A, KDM5C, SETD2, and MLL3 (9) (10) (11) (12) (13) (14) (15) .
Why might ccRCCs frequently mutate chromatin regulators? In normal cells, HIF accumulates under hypoxic conditions and induces many genes that promote adaptation to hypoxia. HIF also induces many chromatin modifiers, including the Jumonji C (JmjC) domaincontaining histone demethylases KDM3A, KDM4B, KDM5C, and KDM6B (16) (17) (18) (19) (20) (21) which, like the EglNs, are dioxygenases. Although the oxygen affinities of the JmjC histone demethylases, and hence their sensitivities to changes in physiological oxygen concentrations,
are not yet fully understood, their induction by HIF might help compensate for their lowered catalytic activity under hypoxic conditions (16, (22) (23) (24) (25) .
However, in pVHL-defective ccRCCs, HIF accumulation is unlinked from oxygen availability, causing the inappropriate activation of HIF target genes, including KDMs. This would theoretically alter histone modifications, chromatin structure, and gene expression. Some of these changes might be deleterious to ccRCC. We hypothesized that chromatin dysregulation caused by VHL inactivation creates the selection pressure to mutate specific chromatin regulators in ccRCC and simultaneously creates dependencies that can be exploited therapeutically.
RESULTS ccRCCs have a distinctive histone modification signature
We first looked for evidence of altered histone modifications associated with pVHL loss using a multiplexed, high-resolution, targeted, quantitative mass spectrometry assay that can simultaneously quantify posttranslational modifications on distinct histone amino acids, irrespective of the availability or efficacy of specific antibodies to candidate histone marks, and that has been validated on cell lines and primary tissue (26, 27) . Using this approach, we analyzed 12 ccRCCs, 12 papillary renal carcinomas (pRCCs), and 12 chromophobe renal carcinomas (chRCCs). Unlike ccRCCs, pRCCs and chRCCs are not typically associated with pVHL loss.
Unsupervised clustering of the histone modification data generated in this way revealed that 11 of the 12 ccRCCs clustered within a clade that was associated with increased amounts of H3K27ac (acetylation) and H3K27me0/me1 (relative hypomethylation), relative to the other clades ( Fig. 1A and fig. S1A ). H3K27ac and H3K27 methylation (particularly me2/me3) are reciprocally related to one another, but changes in H3K27ac are easier to detect (on a fold basis) because of the higher baseline abundance of H3K27me2/me3 relative to H3K27ac in cells ( fig. S1B ). The increase in H3K27me0/me1 was specific to H3K27 because, for example, H3K79me2 was increased in chRCCs relative to ccRCCs (Fig. 1A) . Therefore, ccRCCs exhibit a distinct histone signature associated with increased H3K27ac and H3K27me0/me1.
A few pRCCs were interspersed among the ccRCCs. Independent pathological review of the pRCCs for which tissue blocks were available revealed that the pRCCs that coclustered with the ccRCCs were highgrade, non-type 1 pRCCs with atypical morphology, including areas resembling ccRCC, whereas the pRCCs found in the non-ccRCC clade were typical low-grade, type 1 pRCCs (figs. S2 and S3). To avoid confusion with existing nomenclature, we called these non-type 1 pRCC samples "atypical pRCC." Some pRCCs have high HIF expression due to mutations affecting genes other than VHL (28) . Notably, the atypical pRCC that clustered with ccRCC showed high HIF activity compared to classical pRCC ( fig. S2 ).
VHL and EZH1 are synthetic lethal in ccRCC To determine whether VHL inactivation increases dependence on specific chromatin modifiers, we lentivirally infected eight VHL-deficient ccRCC cell lines (A498, CAKI-2, RCC4, UMRC-2, UMRC-6, UOK101, 769-P, and 786-O) to express pVHL or the parental vector, thereby generating eight isogenic cell line pairs (16 cell lines in total) (figs. S4 and S5A). These cells were then infected in six biological replicates at a low multiplicity of infection with a pool of~1000 lentiviral shRNA vectors targeting 143 enzymes, including the known histone methyltransferases, histone demethylases, and miscellaneous 2-oxoglutaratedependent dioxygenases, as well as negative control targets such as GFP, RFP, LacZ, and Luciferase (four to six shRNAs per gene) (Fig. 1B and  table S1 ). After selection, we serially passaged the infected cells for six to eight passages, harvesting 90% of the population at each passage and propagating the remaining 10% (Fig. 1B) . The abundance of the individual shRNAs was measured by deep sequencing.
Enrichment or depletion of shRNAs in the VHL-deficient cells relative to pVHL-proficient cells was measured using RIGER ( Fig. 1C) (29) . We ranked the shRNAs by logarithmic fold change in their representation over time in the VHL −/− and pVHL-proficient ccRCC cells. We converted the resulting shRNA rankings to their corresponding genes by using the "weighted sum" algorithm after correcting for differences in the number of shRNAs targeting each gene (table S2) . Given our histone profiling data, we focused our attention on genes linked to the control of H3K27 modifications.
shRNAs targeting KDM6A (also called UTX), which encodes an H3K27 demethylase, were enriched over time in the VHL −/− ccRCC cells relative to pVHL-proficient cells (Fig. 1C) , consistent with the knowledge that KDM6A is a ccRCC suppressor (9, 13, 30) . This was specific because shRNAs targeting the KDM6A paralog KDM6B (JMJD3) were, in contrast, depleted in VHL −/− ccRCC cells (Fig. 1C ). EZH1 and EZH2 encode H3K27 methyltransferases. shRNAs targeting EZH1 were depleted in VHL −/− ccRCC cells, although this was primarily driven by just one of the EZH1 shRNAs (number 10708) in the lentiviral pool (Fig. 1D) . This was anomalous because we typically observe three to four effective shRNAs per gene with this library. We therefore analyzed two additional EZH1 shRNAs (numbers 734 and 735) (Fig. 1D) . The two EZH1 shRNAs that most effectively down-regulated EZH1 (10708 and 734) also selectively inhibited VHL −/− ccRCC cells, whereas the relatively ineffective EZH1 shRNAs had minimal effect ( Fig. 1, D fig. S5, F and G) , indicating that their antiproliferative effects were not indirectly due to EZH2 loss.
The fact that our two most effective EZH1 shRNAs also caused the most marked inhibition of VHL −/− ccRCC cells was reassuring but could still have occurred by chance. We therefore pursued multiple strategies to determine whether the effects of the EZH1 shRNAs on VHL −/− ccRCC cell proliferation were on-target and interrogated multiple cell lines to ensure that they were robust. We first documented that the antiproliferative effects of the EZH1 shRNAs 10708 and 734 on VHL −/− cells were reversed by the expression of an shRNA-resistant wild-type EZH1 (Fig. 1F and fig. S6, A and B ), but not a methyltransferase-defective EZH1 mutant (DSET) (Fig. 1F and fig. S6A ).
We also showed that inactivating EZH1 using CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) with two different single-guide RNAs (sgRNAs) preferentially inhibited VHL −/− cells (Fig. 2 , A and B) compared to pVHL-proficient cells. To determine whether the EZH1 sgRNA results were on-target, we introduced a doxycycline (DOX)-inducible EZH1 mRNA into VHL −/− cells and then inactivated the endogenous EZH1 locus in the presence of DOX using CRISPR/Cas9 and a third sgRNA that targets an EZH1 intron-exon junction. Withdrawal of DOX decreased the proliferation of these cells (Fig. 2, C (Fig. 3C ) and the multiplexed mass spectrometry method (Fig. 3D ) described above (Fig. 1A) .
Consistent with our genetic studies, JQ-EZ-05 preferentially inhibited the growth and viability of VHL −/− ccRCC cells compared to their pVHL-proficient counterparts in monolayer assays (Fig. 4 , A to C, and fig. S8 , A to D), soft agar assays (Fig. 4, D and E) , and apoptosis assays (Fig. 4, F and G, and fig. S8E ). Notably, the JQ-EZ-05 concentration required for these antiproliferative effects was about 10-fold higher than needed to inhibit bulk H3K27me3 (Fig. 4A) , which is consistent with the knowledge that the latter is controlled primarily by EZH2 and that the biochemical K i of JQ-EZ-05 for EZH1 is 10 foldhigher than its K i for EZH2 (Fig. 3B) . We observed similar effects with a second EZH inhibitor, GSK-126 ( fig. S8 , F and G). These effects were specific to the EZH inhibitors because we did not observe selective killing of VHL −/− ccRCC with several other cytotoxic agents ( fig. S8 , H to J). Notably, differential suppression of VHL −/− ccRCC cells relative to pVHL-proficient ccRCC cells by JQ-EZ-05 and GSK-126 might be attenuated because, in addition to EZH1, they both inhibit EZH2 and perhaps other targets. We are unaware, however, of drugs that inhibit EZH1, but not EZH2. Finally, JQ-EZ-05 impeded VHL −/− ccRCC cells in orthotopic tumor assays in vivo (Fig. 4 , H to J), without measured by mass spectrometry analysis (described in fig. S1 ), in renal tumor samples annotated as ccRCCs, typical pRCCs (type 1), atypical pRCCs, and chRCCs. P values were calculated using Student's t test, and P < 0.05 was considered significant. NS, not significant. (B) Short hairpin RNA (shRNA) screen schema. (C) Genes whose shRNAs exhibited the greatest depletion or enrichment in the VHL −/− ccRCC relative to isogenic pVHL-proficient cells, as determined by RIGER. (D) Immunoblots of UMRC-2 cells that were lentivirally infected to produce pVHL and then stably infected to produce the indicated EZH1 shRNAs or an shRNA against firefly luciferase (Luc). The shRNAs in the screen are indicated in red. (E) Crystal violet staining of UMRC-2 that were lentivirally infected to produce pVHL (VHL) or infected with an empty lentivirus (VEC) and then stably infected to produce the indicated EZH1 shRNAs or an shRNA against firefly luciferase (Luc). (F) Photomicrographs of CAKI-2 cells that were infected to produce exogenous wild-type (WT) EZH1, catalytic-dead EZH1 (DSET), or with the empty vector (VEC) and then with a lentivirus encoding an EZH1 shRNA (10708) or control shRNA. The EZH1 WT vector contained synonymous mutations in the sequence recognized by the 10708 shRNA. The DSET mutation also eliminates the 10708 recognition sequence.
being grossly toxic, as determined by the stable body weights of treated mice (Fig. 4K ).
In general, the sensitivity of VHL −/− ccRCC cell lines to JQ-EZ-05 mirrored the degree to which EZH1 shRNAs were depleted in those lines in our initial screen ( fig. S9A ), which suggested that EZH1 was the relevant target of JQ-EZ-05 in our assays. To more formally address whether the antiproliferative effects of JQ-EZ-05 on VHL −/− ccRCC cells were on-target, we determined whether they could be reversed by JQ-EZ-05-resistant EZH1 variants, identified using two different approaches.
The primary sequences of the EZH1 and EZH2 catalytic SET domains that are predicted to bind to JQ-EZ-05 are highly similar (Fig. 5A ). Their different JQ-EZ-05 K i values, however, suggest that one or more regions of sequence dissimilarity within or adjacent to these domains influence JQ-EZ-05 interaction. Eliminating one such region ("PSET"; residues 744 to 747, Fig. 5A ) in EZH1 rendered EZH1 partially insensitive to JQ-EZ-05, and apparently more "EZH2-like" with respect to the control of bulk H3K27me3 (see also below), in cell-based pharmacodynamic assays (Fig. 5B) . Introduction of this EZH1 variant (DPSET) into VHL −/− ccRCC cells also blunted the antiproliferative effects of JQ-EZ-05 (Fig. 5C ).
We also randomly mutagenized a lentiviral EZH1 expression plasmid by propagating it in error-prone Escherichia coli (XL1-Red) (31) (32) (33) . We then infected VHL −/− ccRCC cells with the resulting lentiviral pool and grew them in the presence of JQ-EZ-05. As expected, we observed more resistant cells after infection with this pool compared to cells infected with an identical virus encoding wild-type EZH1 or green fluorescent protein (GFP) (Fig. 5D ). Moreover, JQ-EZ-05's effect on H3K27me3 after 3 weeks was slightly attenuated in the polyclonal cells that received the mutagenized EZH1 relative to newly infected cells that were infected to produce wild-type EZH1 or GFP (Fig. 5E ), suggesting that some of the EZH1 random variants could, like the DPSET variant, assume EZH2-like properties. We pooled the resistant cells and used next-generation sequencing to identify the enriched EZH1 variants, which were then individually cloned and studied in secondary assays. We confirmed that two such variants, Y727F and D745N, conferred partial resistance to JQ-EZ-05 in cell viability assays (Fig. 5F  and fig. S9, B to D) .
In biochemical and cell-based assays, we confirmed decreased binding of JQ-EZ-05 to the D745N and DPSET EZH1 variants (fig. S9, E and F), which argues that these variants confer resistance by restoring EZH1 catalytic activity in the presence of JQ-EZ-05 rather than by drug sequestration. In contrast, despite the modeled proximity of Y727 to the putative JQ-EZ-05 binding site within EZH1 (Fig. 5G) , we did not observe decreased binding of JQ-EZ-05 to the Y727F variant in such biochemical and cellular assays. One possibility, among many, is that the Y727F mutation attenuates JQ-EZ-05's effect on EZH1 catalytic activity in vivo, perhaps by increasing EZH1's affinity for S-adenosyl methionine (SAM) or EZH1's k cat . The D745N and Y727F EZH1 variants, unlike the DPSET EZH1 mutant, had little (D745N) or no Cell counts of both VEC and VHL cells were determined 18 days after selection and are presented as fold change after normalization to the number of viable sgControl expressing cells (n = 3, means ± SD). P values were calculated using Student's t test. *P < 0.05 (significant). (C to E) Immunoblots (C), viable cell counts determined by Vi-CELL (D) (n = 3, means ± SD), and photomicrographs (E) of UMRC-2 cells infected with a DOX-inducible EZH1 expression vector and then transduced to express sgRNAs designed to inactivate the endogenous EZH1 locus (INEX2) or, as a control, an ineffective sgRNA. Analysis in (C) was done after expressing the indicated sgRNA for 10 days. DOX was present for the first 7 days and then maintained (+) or withdrawn (−) for 3 days. (D) and (E) were done 18 days after DOX withdrawal. P values were calculated using Student's t test. *P < 0.05 (significant).
(Y727F) discernable effect on the loss of bulk H3K27me3 caused by JQ-EZ-05 ( Fig. 5H and fig. S9G ), consistent with EZH2 being responsible for most H3K27me3 in cells (34) . The fact that all three EZH1 variants, including the Y727F variant, rescued VHL −/− ccRCC cell viability in the face of a dual EZH1/2 inhibitor suggests that EZH1 has genomic locus-specific effects that are not reflected in bulk H3K27me3 measurements. Alternatively, the requirement for EZH1 in VHL −/− ccRCC might be due to a noncanonical EZH1 histone-modifying activity or perhaps a nonhistone substrate.
Histone demethylase activity driven by HIF underlies the need for EZH1 in VHL −/− ccRCC Suppression of HIF-dependent transcription under normoxic conditions is the canonical function of pVHL (3) . Strikingly, eliminating the obligate HIFa DNA binding partner ARNT1 (aryl hydrocarbon receptor nuclear translocator 1) with CRISPR/Cas9 rescued the fitness defect caused by EZH1 loss in VHL-deficient cells [Fig. 6 , A to D (in cells described earlier in Fig. 2, C to E) ]. Similarly, down-regulating ARNT using two highly effective shRNAs or with CRISPR/Cas9 conferred resistance to JQ-EZ-05 (Fig. 6, E to H, and fig. S10, A and B) . This strongly suggests that the increased requirement for EZH1 in VHL −/− ccRCC is caused by HIF deregulation.
Gene Set Enrichment Analysis (GSEA) (35) , comparing the transcriptional profiles in VHL −/− 786-O ccRCC cells (high HIF) to 786-O cells in which ARNT1 was depleted (low HIF) with either an effective shRNA (Fig. 6E) or sgRNA (Fig. 6G) , revealed a gene signature consistent with the loss of H3K27me3 in cells with high HIF (Fig. 7A and tables S3 and S4). This further suggested that an HIF-responsive gene(s) caused the reduced H3K27me3 in VHL −/− ccRCC cells and their dependence on EZH1 activity. Moreover, we consistently noted that compared to their VHL −/− counterparts, the pharmacodynamic effects of JQ-EZ-05 on H3K27me3 were blunted in lentivirally reconstituted (Fig. 4A and fig. S11, A and B) and naturally occurring pVHLproficient renal cells ( fig. S11C) , and restoration of pVHL function in VHL-deficient cells increased H3K27me3 ( fig. S11D ), suggesting that VHL −/− ccRCC cells have either increased H3K27 demethylase activity or decreased H3K27 methyltransferase activity. In support of the former, we observed that extracts from VHL-deficient cells demethylate H3K27, In (E), three representative fields were quantified from each biological replicate. In (C) and (E) (n = 3, means ± SD), P values were calculated using Student's t test, and P < 0.05 considered significant. (F and G) Apoptosis, as measured by annexin V staining (y axis) (F) and resulting quantification (G), of UMRC-2 cells infected with a lentivirus encoding pVHL (VHL) or empty vector (VEC) that were treated with the indicated concentrations of JQ-EZ-05 for 8 days. P values were calculated using Student's t test, and P < 0.05 was considered significant. (H and I) Bioluminescence imaging (BLI) of nonobese diabetic/severe combined immunodeficient mice orthotopically injected with UMRC-2 cells engineered to produce firefly luciferase. Once tumors were established, as determined by serial BLI, mice were randomized (day 0) to JQ-EZ-05 (75 mg/kg, intraperitoneally, three times per week) or vehicle. Representative images (H) and quantification (I) of change in tumor burden on day 45 relative to day 0, as determined by BLI. In (I), P values were calculated by using the nonparametric Mann-Whitney U test, and P < 0.05 was considered significant. (J) Representative images of kidneys excised from tumor-bearing mice at necropsy after treatment as described in (H) and (I) or from an age-and sex-matched control mouse without any orthotopic tumors ("Neg."). (K) Body weights of mice (n = 3, means ± SD) after the indicated duration of treatment with either vehicle or JQ-EZ-05 (75 mg/kg, intraperitoneally, three times per week). 
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but not H3K9, on calf thymus core histones more rapidly than extracts from pVHL-proficient cells (Fig. 7B) . Together, these results indicate that pVHL loss increases H3K27 demethylase activity. The two canonical H3K27 demethylases, KDM6A (UTX) and KDM6B (JMJD3), are induced by hypoxia, and KDM6B is a HIF target gene (21) . Consistent with this, we noted increased KDM6B protein in VHL-deficient cells compared to their pVHL-proficient counterparts, except in RCC4 cells, which did not exhibit pVHL-dependent sensitivity to EZH1 shRNAs or to JQ-EZ-05 (figs. S9A and S12A). Although KDM6B can be regulated by HIF1a (21), KDM6B levels were decreased by ARNT sh/sgRNAs in 786-O cells, which contain HIF2a and not HIF1a, suggesting that KDM6B can be regulated by HIF2a ( fig. S12B ). Consistent with this notion, eliminating HIF2a with CRISPR/Cas9 in UMRC-2 cells, which contain both HIF1a and HIF2a (7), down-regulated KDM6B (Fig. 7C ) and conferred partial resistance to JQ-EZ-05 (Fig. 7D) . Finally, down-regulation of KDM6B, but not KDM6A, with two effective shRNAs in VHL −/− ccRCC cells conferred partial resistance to JQ-EZ-05 (Fig. 7E and fig. S12, C and D) . Therefore, deregulation of HIF-responsive demethylases, and particularly KDM6B, increases the dependence of VHL −/− ccRCCs on EZH1 activity. To look for further evidence that EZH1 and KDM6B counterbalance one another in human ccRCCs, we analyzed renal cancer data from The Cancer Genome Atlas consortium using Oncomine (36) . We observed that EZH1 and EZH2 mRNAs were both increased in advanced stage renal tumors ( fig. S13A ), suggesting a nonredundant role for these enzymes in ccRCC. Furthermore, EZH1 mRNA, but not EZH2 mRNA, was significantly (P < 0.05) higher in ccRCC tumors, which are typically associated with VHL loss, as compared to pRCC, which typically retain wild-type pVHL ( fig. S13B) . Likewise, the mRNA for KDM6B, but not KDM6A, H3K27 demethylase was increased in ccRCC versus pRCC ( fig. S13B) .
pVHL influences the transcriptional response to EZH1 inactivation To begin understanding the biological processes regulated by EZH1 in VHL −/− ccRCC cells, we measured changes in mRNA abundance after pharmacological (treatment with JQ-EZ-05) (Fig. 8A) or genetic (sgRNA-mediated) (Fig. 8B) inactivation of EZH1 and performed GSEA. Because JQ-EZ-05 inhibits both EZH1 and EZH2, we treated cells expressing wild-type EZH1 and cells expressing the EZH1 Y727F JQ-EZ-05-resistant variant (Fig. 5F ) with JQ-EZ-05, reasoning that mRNA changes observed in the former, but not the latter, would be directly or indirectly regulated by EZH1. We focused specifically on gene sets that are induced upon EZH1 loss because H3K27me3 is usually a repressive mark. This analysis identified 17 gene sets regulated by EZH1 in ccRCC, which included genes linked to sterol biosynthesis, oxidative phosphorylation, and the p53 response network (Fig. 8C and  table S5) .
A potential link between EZH1 and sterol biosynthesis is noteworthy because dysregulated fatty acid metabolism is believed to cause the "clear cell" phenotype of VHL-deficient ccRCC. We confirmed that multiple SREBP (sterol regulatory element-binding protein)-responsive mRNAs, including the HMGCS1 and SQLE mRNAs, are far more induced after EZH1 inactivation in VHL −/− ccRCC cells than in their pVHL-proficient counterparts (Fig. 8, D and E) . Therefore, pVHL loss alters the transcriptional response to EZH1 inactivation in ccRCC.
GSEA defines biomarkers associated with EZH1-VHL synthetic lethality To begin identifying predictive biomarkers for EZH1 dependence, we performed GSEA on VHL −/− ccRCC lines in which EZH1 did (synthetic lethality, "present") or did not (synthetic lethality, "absent") score as synthetic lethal (fig. S14A ). We found that some of the top-ranking gene sets in the former represent a signature of polycomb repressive complex 2 (PRC2) targets (genes induced upon loss of PRC2 complex) ( fig. S14B  and table S6) . Functionally, such a signature reflects a loss of H3K27me3, consistent with increased H3K27 demethylase activity increasing the dependence on EZH1 in these cells.
This still did not explain why only the loss of KDM6B, but not KDM6A, reversed the dependence on EZH1. We hypothesized that KDM6A was already down-regulated in some of our ccRCC cell lines because it is a ccRCC suppressor or that increased PRC2 activity in the sensitive cells might also feedback-suppress KDM6A. Comparing the expression of KDM6A in all eight ccRCC lines revealed that cell lines displaying synthetic lethality had reduced KDM6A compared to the cell lines where synthetic lethality was absent ( fig. S14, C and D) . These analyses reveal that the VHL −/− ccRCC cell lines that are hypersensitive to the loss of EZH1 H3K27 methyltransferase activity have a gene expression signature consistent with H3K27 hypomethylation and probably depend primarily on KDM6B for H3K27 homeostasis because of decreased KDM6A.
DISCUSSION
Large-scale small interfering RNA/shRNA (si/shRNA) screens in mammalian cells are often complicated by signal-to-noise problems, especially when looking at si/shRNA depletion, such as in synthetic lethal screens, rather than enrichment. This noise stems from multiple factors, including si/shRNA off-target effects and potential confounding biological factors related to cell type-specific differences in, for example, target knockdown efficiency, cell proliferation rates, and genetic background. In an attempt to mitigate these technical concerns and to identify genetic interactions that would be biologically robust, we performed shRNA screens in eight isogenic VHL −/− and pVHL-proficient ccRCC pairs in six biological replicates. Notably, pVHL status does not affect cell proliferation under standard conditions (37) . Rather than performing genome-wide screens, we focused on chromatin-modifying enzymes, knowing that deregulation of HIF, which is a ccRCC hallmark, alters the expression of many JmjC histone demethylases (16) (17) (18) (19) (20) (21) , and knowing that chromatin-modifying genes are frequently mutated in this disease (9) (10) (11) (12) (13) (14) (15) . These two observations might be linked, with the former contributing to the selection pressure for the latter. Specifically, the chromatin-associated mutations in ccRCC might arise to mitigate or amplify the effects of HIF-responsive chromatin modifiers that would otherwise suppress or enhance tumor growth, respectively.
Our screens identified many candidate VHL synthetic lethal interactors, including the H3K27 methyltransferase EZH1. We prioritized EZH1 because we found that ccRCCs display a distinctive H3K27 methylation profile and because the KDM6A (UTX) H3K27 demethylase is a known ccRCC tumor suppressor (9, 15) . KDM6A shRNAs were enriched in VHL −/− ccRCC cells in our screen, consistent with such a role. Our studies suggest that pVHL loss increases the requirement for EZH1 because of the HIF-dependent increase in H3K27 demethylase activity.
The findings in many cancer target validation papers have been found to be not reproducible or not robust (38) . We ensured that the antiproliferative effects of EZH1 shRNAs in VHL −/− ccRCC cells were rescued by restoring the expression of EZH1 with an shRNA-resistant mRNA, and we corroborated our shRNA results with two orthogonal approaches: elimination of EZH1 with CRISPR/Cas9 and pharmacological inhibition of EZH1 methyltransferase activity, again with controls to ensure that the effects we observed were on-target. Finally, we demonstrated that EZH1 dependence is observed in multiple VHL −/− ccRCC cells.
A recent study predicted, on the basis of in silico considerations, that EZH1 would be synthetic lethal with VHL (39). Ironically, that study dismissed EZH1 because it did not validate in the one cell line tested (RCC4), consistent with our own results in that cell line, underscoring the need to test multiple cell lines.
Our work supporting EZH1 as a potential target in ccRCC contrasts with previous studies suggesting that EZH2, which did not score in our synthetic lethal screen, is a viable therapeutic target in ccRCC (40, 41) . EZH2 is overexpressed in ccRCC and associated with a poor prognosis (41) . Overexpression and association with a poor prognosis, however, are neither necessary nor sufficient to be an effective cancer drug target (38) . Previous studies that interrogated the requirement for EZH2 in ccRCC used a limited number of EZH2 si/shRNAs, without rigorously establishing that their effects were on-target (40, 41) , and in one case, DZNep (41), which inhibits S-adenosylhomocysteine hydrolase and thereby indirectly targets many SAM-dependent enzymes.
Our findings suggest that EZH1 and EZH2 have nonredundant functions in ccRCC. The existence of such paralog-specific functions is coming to light (42) (43) (44) (45) (46) (47) . For example, EZH1 can promote transcriptional elongation, whereas EZH2 can be a transcriptional coactivator independently of its canonical role in the PRC2 (43) (44) (45) (46) (47) . In a similar vein, we noted that shRNAs against KDM6B (JMJD3) were depleted in VHL −/− ccRCC cells, suggesting a tumor-promoting role for KDM6B, in contrast to the tumor suppressor activity of KDM6A (UTX). Similarly, KDM6B and KDM6A play opposing roles in T cell acute lymphoblastic leukemia (48) , and KDM6B, but not KDM6A, is a pediatric brainstem glioma oncogene (49) . It will be important to begin to understand the biochemistry, including downstream target genes, underlying these paralog-specific functions.
Our findings are entirely consistent with earlier studies showing that EZH2, and not EZH1, is responsible for most of the global H3K27me3 in cells (34) , and these findings support a model wherein EZH1 controls ccRCC fitness by acting locally to control H3K27me3 at specific genomic loci ( fig. S14E ). Consistent with this hypothesis, we identified specific gene sets that respond to EZH1 loss in ccRCC in a pVHL-dependent manner. These gene sets can be viewed as biomarkers for EZH1 status in ccRCC and might also play a causal role in the synthetic lethality between EZH1 and VHL. Clearly, additional studies, including genetic epistasis experiments, will be required to identify the direct EZH1 target genes, and perhaps noncanonical targets, in ccRCC that link EZH1 activity to ccRCC fitness. Some bona fide tumor suppressor genes, such as KDM6A and MLL3, scored as potential tumor suppressors by virtue of shRNA enrichment in our screen, but others, such as SETD2 and KDM5C, did not. This could be due to technical factors, such as the adequacy of their corresponding shRNAs, or because we ranked genes based on relative enrichment or depletion in VHL −/− ccRCC cells compared to pVHLproficient cells. In particular, genes that, when inactivated, cause a fitness advantage regardless of pVHL status would not have scored in our assays but might be revealed by examining shRNA depletion or enrichment as a function of time irrespective of pVHL. It is also possible that these genes, or the pathways in which their protein products operate, are already crippled in some of our ccRCC lines.
Although we focused on EZH1, our screen identified additional putative VHL synthetic lethal interactors that can now be pursued further. For example, the H3K36 demethylase KDM4A (JMJD2A), which can act as an oncogene (50, 51) , also scored as synthetic lethal with VHL in our screen. It is tempting to speculate that KDM4A opposes the actions of the SETD2 H3K36 methyltransferase, which is lost in a subset of ccRCC.
Our studies nominate EZH1 as a therapeutic target in ccRCC. However, it is important to note that the JQ-EZ-05 median inhibitory concentration in VHL −/− ccRCC cells was not as low as in EZH2-mutant lymphomas, and the selectivity for VHL −/− ccRCC cells relative to pVHLproficient cells was not as great as the selectivity for EZH2-mutant lymphoma relative to EZH2 wild-type lymphoma. Moreover, the antitumor effects of JQ-EZ-05 for VHL −/− ccRCCs in vivo were markedly reduced in mice with high tumor burdens. On the other hand, JQ-EZ-05 more potently inhibits EZH2 than EZH1 in biochemical assays in vitro and has not been optimized for in vivo bioavailability. It will be of interest to test bioavailable EZH1-selective inhibitors for their efficacy in VHL −/− ccRCC as they become available.
MATERIALS AND METHODS

Study design
The objective of this work was to study the epigenetic changes associated with VHL loss in ccRCCs, with the hope of identifying potentially targetable dependencies. The sample size for the histone modification analysis was determined by the availability of tumor samples. Researchers preparing and analyzing histone profiles were blinded to the source and annotation of renal tumors. The sample size (six biological replicates) for the shRNA mini-pool screen was based on previous experience. Early results identified EZH1 as a candidate target. Cell culture experiments to establish the effects of EZH1 loss on pVHL-proficient and VHL −/− cells were done at least twice, typically three to five times. All data are presented as means ± SD, unless specified otherwise in the legend. The end points, culture conditions, etc., for the cell culture experiments were determined based on previous work using these ccRCC cell lines. The methods used to do these experiments, including primer sequences (table S7), are described in detail in the Supplementary Materials and Methods and outlined in the figure legends. Statistical tests used to establish significance and associated P values are described in the figure legends. For in vivo experiments, we relied on a previously established mouse model to study the growth of VHLdeficient ccRCC cells implanted orthotopically into mouse kidneys. The sample size and duration of treatment were based on previous knowledge regarding the rate of UMRC-2 tumor growth, and we anticipated 45 to 60 days of treatment. Randomization of animals into the different treatment groups was performed after measuring tumor burden using bioluminescent imaging 2 weeks after orthotopic injection of ccRCC cells. The randomization process was designed to assign a similar number of mice with comparable tumor burdens to each treatment arm. Researchers were blinded to the treatment arms during image collection. Detailed experimental procedures are provided in the Supplementary Materials.
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